NCT02762643View on ClinicalTrials.gov

DP-R213 Pharmacokinetics Study

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

July 31, 2016

Study Completion Date

August 31, 2016

Conditions
Healthy
Interventions
DRUG

DP-R213

Investigational product is prescribed to all of randomized subjects

DRUG

Raloxifene

Investigational product is prescribed to all of randomized subjects

DRUG

Cholecaliferol

Investigational product is prescribed to all of randomized subjects

Sponsors

Lead Sponsor

Alvogen Korea
All Listed Sponsors
lead

Alvogen Korea

INDUSTRY

NCT02762643 - DP-R213 Pharmacokinetics Study | Biotech Hunter | Biotech Hunter